AHA Coding Clinic® for HCPCS - 2013 Quarter 2; For Your Information
Drugs and biologicals with OPPS pass-through status
Effective April 1, 2013, these drugs and biologicals were added to the list of drugs and biologicals with OPPS pass-through status. HCPCS code Long descriptor C9130 Injection, immune globulin (Bivigam), 500 mg C9297 Injection, omacetaxine mepesuccinate, 0.01 mg C9298 Injection, ocriplasmin, 0.125 mg J7315 Mitomycin, ophthalmic, 0.2 mg Q4127 Talymed, per square centimeter ...
Subscribe or sign in to view the full article.
Article Overview
This premium article is a concise HCPCS-focused update for hospital outpatient billing and coding. It lists drugs and biologicals that were added to the OPPS pass-through status list effective April 1, 2013, helping coders and billing staff verify which products are included in the update.
Why This Topic Matters
This matters for outpatient prospective payment system reporting and charge capture because it documents a specific effective-date update to the pass-through status list. It is useful for anyone validating hospital outpatient drug and biological coding against the April 2013 update.
What You Will Learn
- Which drugs and biologicals were added in the April 1, 2013 OPPS pass-through update.
- How this update is organized as a short list of HCPCS-reported items.
- Which HCPCS identifiers are associated with the update.
- intended_audiences([
Who Should Read This
- Hospital outpatient coders
- Billing staff
- Revenue cycle teams
- Compliance reviewers
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com